Montreal-based biotechnology company Innospera Pharma has appointed Dr. Glenn Crater, MD, FCCP as Chief Medical Officer to support the clinical advancement of its lead compound ING-006, a novel treatment for Idiopathic Pulmonary Fibrosis (IPF). Dr. Crater will begin immediately as a fractional CMO, with plans to transition to full-time as the company's lead compound enters clinical trials.
Strategic Leadership Addition
Dr. Crater brings over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development to Innospera. As a board-certified pulmonologist, he has played pivotal roles in advancing respiratory drug candidates, with particular expertise in IPF—the initial target indication for ING-006, which is poised to enter clinical development in the near future.
"We are thrilled to welcome Glenn to Innospera at this critical moment in our growth," said François Ravenelle, PhD, Chief Executive Officer of Innospera. "Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators."
Novel Therapeutic Approach
ING-006 represents a first-in-class synthetic lipid designed to address IPF by resolving inflammation and reducing fibrogenesis through modulation of GPR84 and GPR40 receptors. This approach targets GPCR lipid signaling pathways to restore homeostasis in diseases driven by metabolic and inflammatory dysfunction.
"I'm excited to reunite with François and the team at Innospera," said Dr. Crater. "ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases."
Clinical Development Experience
Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases.
Company Background
Innospera is developing first-in-class GPR84 and GPR40 modulators to treat inflammatory and metabolic diseases. The company is backed by a strong syndicate of investors including Investissement Québec, Seido Capital, and Anges Québec. The appointment positions the company to advance its clinical pipeline as ING-006 approaches its first-in-human studies.
